ONCOLYTICS BIOTECH INC (ONC.CA) Stock Overview
TSX:ONC - CA6823108759 - Common Stock
ONC.CA Key Statistics, Chart & Performance
The current stock price of ONC.CA is 1.42 CAD. In the past month the price decreased by -7.19%. In the past year, price increased by 5.97%.
ONC.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 423.01M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 347.88M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 256.75M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 205.53M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 190.28M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 96.41M | ||
| WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 88.12M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 87.58M | ||
| BLU.CA | BLUENERGIES LTD | N/A | 69.74M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 18.46 | 65.81M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 60.21M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 48.52M |
Related stock screener links
About ONC.CA
Company Profile
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 29
Phone: 14036707377
ONCOLYTICS BIOTECH INC / ONC.CA FAQ
What is the stock price of ONCOLYTICS BIOTECH INC today?
The current stock price of ONC.CA is 1.42 CAD. The price increased by 2.16% in the last trading session.
What is the ticker symbol for ONCOLYTICS BIOTECH INC stock?
The exchange symbol of ONCOLYTICS BIOTECH INC is ONC and it is listed on the Toronto Stock Exchange exchange.
On which exchange is ONC.CA stock listed?
ONC.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for ONCOLYTICS BIOTECH INC stock?
8 analysts have analysed ONC.CA and the average price target is 4.6 CAD. This implies a price increase of 224.02% is expected in the next year compared to the current price of 1.42. Check the ONCOLYTICS BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ONCOLYTICS BIOTECH INC worth?
ONCOLYTICS BIOTECH INC (ONC.CA) has a market capitalization of 126.12M CAD. This makes ONC.CA a Micro Cap stock.
How many employees does ONCOLYTICS BIOTECH INC have?
ONCOLYTICS BIOTECH INC (ONC.CA) currently has 29 employees.
What are the support and resistance levels for ONCOLYTICS BIOTECH INC (ONC.CA) stock?
ONCOLYTICS BIOTECH INC (ONC.CA) has a support level at 1.42 and a resistance level at 1.5. Check the full technical report for a detailed analysis of ONC.CA support and resistance levels.
Should I buy ONCOLYTICS BIOTECH INC (ONC.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONC.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONC.CA, evaluating the profitability, health, valuation and growth aspects
- ONCOLYTICS BIOTECH INC (ONC.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ONCOLYTICS BIOTECH INC (ONC.CA) Sales and EPS estimates to see what analysts future expectations are.
- ONCOLYTICS BIOTECH INC (ONC.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ONCOLYTICS BIOTECH INC (ONC.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ONCOLYTICS BIOTECH INC (ONC.CA) Stock Chart to make your own analysis
- ONCOLYTICS BIOTECH INC (ONC.CA) Latest news and press-releases to stay up to date.
Does ONCOLYTICS BIOTECH INC (ONC.CA) stock pay dividends?
ONC.CA does not pay a dividend.
When does ONCOLYTICS BIOTECH INC (ONC.CA) report earnings?
ONCOLYTICS BIOTECH INC (ONC.CA) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of ONCOLYTICS BIOTECH INC (ONC.CA)?
ONCOLYTICS BIOTECH INC (ONC.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
ONC.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ONC.CA. When comparing the yearly performance of all stocks, ONC.CA is one of the better performing stocks in the market, outperforming 91.85% of all stocks.
ONC.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONC.CA. While ONC.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ONC.CA Financial Highlights
Over the last trailing twelve months ONC.CA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 2.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.26% | ||
| ROE | -499.46% | ||
| Debt/Equity | 0.1 |
ONC.CA Forecast & Estimates
8 analysts have analysed ONC.CA and the average price target is 4.6 CAD. This implies a price increase of 224.02% is expected in the next year compared to the current price of 1.42.